Literature DB >> 2152795

M1 muscarinic acetylcholine receptor in cultured rat neostriatum regulates phosphoinositide hydrolysis.

P T Akins1, D J Surmeier, S T Kitai.   

Abstract

Muscarinic acetylcholine receptor expression and function in cultured rat neostriatal neurons were examined. All experiments were performed on intact neurons grown in vitro for 12-14 days. The muscarinic antagonist N-[3H]methylscopolamine [( 3H]NMS) binds to a single site in cultures with a KD of 89 pM and a Bmax of 187 fmol/mg of protein, or 32,000 sites/neuron. Competition studies using [3H]NMS were performed to determine what receptor subtypes were present. Nonlinear analysis of competition curves was best described with a single binding site for atropine, pirenzepine, and AF-DX 116 (11-[[2-[(diethylamino)-methyl]-1-piperidinyl]acetyl]-5,11-dihydro- 6H-pyrido[2,3-b][1,4]benzodiazepine-6-one), with Ki values of 0.6, 62, and 758 nM, respectively. These results indicate that the muscarinic receptors present in neostriatal cultures are of the M1 subtype, having high affinity for pirenzepine and low affinity for AF-DX 116. In contrast with antagonists, carbachol displaced [3H]NMS from two sites with Ki values of 6.5 and 147 microM, with the higher-affinity form predominant (83% of sites). The M1 receptor subtype was linked to phosphoinositide turnover. Carbachol stimulated the formation of phosphoinositides with an EC50 of 37 microM and was antagonized by atropine. At equimolar doses, pirenzepine was more potent than AF-DX 116 at antagonizing the response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2152795     DOI: 10.1111/j.1471-4159.1990.tb13310.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons.

Authors:  Xiaohui Lv; Jonathan W Dickerson; Jerri M Rook; Craig W Lindsley; P Jeffrey Conn; Zixiu Xiang
Journal:  Neuropharmacology       Date:  2017-03-20       Impact factor: 5.250

2.  Thalamic gating of corticostriatal signaling by cholinergic interneurons.

Authors:  Jun B Ding; Jaime N Guzman; Jayms D Peterson; Joshua A Goldberg; D James Surmeier
Journal:  Neuron       Date:  2010-07-29       Impact factor: 17.173

Review 3.  Cholinergic modulation of synaptic integration and dendritic excitability in the striatum.

Authors:  Ian Antón Oldenburg; Jun B Ding
Journal:  Curr Opin Neurobiol       Date:  2011-06       Impact factor: 6.627

Review 4.  Roles of centromedian parafascicular nuclei of thalamus and cholinergic interneurons in the dorsal striatum in associative learning of environmental events.

Authors:  Ko Yamanaka; Yukiko Hori; Takafumi Minamimoto; Hiroshi Yamada; Naoyuki Matsumoto; Kazuki Enomoto; Toshihiko Aosaki; Ann M Graybiel; Minoru Kimura
Journal:  J Neural Transm (Vienna)       Date:  2017-03-21       Impact factor: 3.575

5.  D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade.

Authors:  S Hernandez-Lopez; T Tkatch; E Perez-Garci; E Galarraga; J Bargas; H Hamm; D J Surmeier
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

6.  Differential excitability and modulation of striatal medium spiny neuron dendrites.

Authors:  Michelle Day; David Wokosin; Joshua L Plotkin; Xinyoung Tian; D James Surmeier
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

7.  Effects of ginsenosides on carbachol-stimulated formation of inositol phosphates in rat cortical cell cultures.

Authors:  Jun-Ho Lee; Seok Choi; Jong-Hoon Kim; Jong-Keun Kim; Jae-il Kim; Seung-Yeol Nah
Journal:  Neurochem Res       Date:  2003-09       Impact factor: 3.996

Review 8.  The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?

Authors:  Won Je Jeon; Brian Dean; Elizabeth Scarr; Andrew Gibbons
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.